IP Library Granted Patent US 8,021,849
Granted Patent B2
US 8,021,849 · App. 10/983,137 · Granted Sep 20, 2011

Methods and kits for the determination of sirolimus in a sample

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,021,849
App. No.
10/983,137
Granted
Sep 20, 2011
Kind
B2
Abstract

Methods and kits for determining sirolimus in a sample known or suspected to contain sirolimus are provided. The methods and kits according to the invention use one or more antibodies generated using a fragment of sirolimus, such as the northern fragment of sirolimus.

Claims (28)

1. A method for determining sirolimus in a sample, comprising:

providing a sample known or suspected to contain sirolimus;

providing an antibody preparation comprising one or more antibodies generated using a compound consisting of the formula:

contacting the antibody preparation with the sample; and

detecting binding between the one or more antibodies and sirolimus.

2. The method for determining sirolimus in a sample according to claim 1 , wherein the sample comprises a human sample.

3. The method for determining sirolimus in a sample according to claim 1 , wherein the sample comprises a whole blood sample.

4. The method for determining sirolimus in a sample according to claim 1 , wherein the antibody preparation comprises a monoclonal antibody.

5. The method for determining sirolimus in a sample according to claim 4 , wherein the monoclonal antibody specifically binds whole sirolimus and does not specifically bind metabolized sirolimus.

6. The method for determining sirolimus in a sample according to claim 4 , wherein the monoclonal antibody is bound to a solid particle.

7. The method for determining sirolimus in a sample according to claim 1 , wherein the one or more antibodies specifically bind whole sirolimus and do not specifically bind metabolized sirolimus.

8. The method for determining sirolimus in a sample according to claim 1 , wherein the antibody preparation comprises one or more antibodies generated using a compound consisting of the formula:

bound to a carrier.

9. The method for determining sirolimus in a sample according to claim 8 , wherein the carrier comprises a protein.

10. The method for determining sirolimus in a sample according to claim 9 , wherein the carrier comprises one of ovalbumin, keyhole limpet hemocyanin, and hen eggwhite lysozyme.

11. The method for determining sirolimus in a sample according to claim 1 , further comprising the step of determining the concentration of sirolimus in the sample based upon the step of detecting binding between the one or more antibodies and sirolimus.

12. A method for determining a concentration of sirolimus in a sample, the method comprising:

contacting a sample known or suspected to contain sirolimus with an antibody preparation comprising one or more antibodies generated using a compound consisting of the formula:

determining the concentration of sirolimus in the sample by correlating the binding between the one or more antibodies and sirolimus in the sample to a series of known concentrations of sirolimus.

13. The method for determining a concentration of sirolimus in a sample according to claim 12 , wherein the sample comprises a human sample.

14. The method for determining a concentration of sirolimus in a sample according to claim 12 , wherein the sample comprises a whole blood sample.

15. The method for determining a concentration of sirolimus in a sample according to claim 12 , wherein the antibody preparation comprises a monoclonal antibody.

16. The method for determining a concentration of sirolimus in a sample according to claim 15 , wherein the monoclonal antibody specifically binds whole sirolimus and does not specifically bind metabolized sirolimus.

17. The method for determining a concentration of sirolimus in a sample according to claim 15 , wherein the monoclonal antibody is bound to a solid particle.

18. The method for determining a concentration of sirolimus in a sample according to claim 12 , wherein the one or more antibodies specifically bind whole sirolimus and do not specifically bind metabolized sirolimus.

19. The method for determining a concentration of sirolimus in a sample according to claim 12 , wherein the antibody preparation comprises one or more antibodies generated using the compound bound to a carrier.

20. The method for determining a concentration of sirolimus in a sample according to claim 19 , wherein the carrier comprises a protein.

21. The method for determining a concentration of sirolimus in a sample according to claim 20 , wherein the carrier comprises one of ovalbumin, keyhole limpet hemocyanin, and hen eggwhite lysozyme.

Assignments (3)
MERGER Recorded Mar 25, 2008
From: DADE BEHRING INC.
To: SIEMENS HEALTHCARE DIAGNOSTICS INC.
Reel/Frame 020690/0530 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2005
From: DEUTSCHE BANK AG, NEW YORK BRANCH
To: DADE BEHRING INC.
Reel/Frame 015956/0726 →
GRANT OF SECURITY INTEREST Recorded Jan 27, 2005
From: DADE BEHRING, INC.
To: DEUTSCHE BANK AG
Reel/Frame 015627/0457 →